mhra

MHRA publishes second-quarter results report for 2026–2027

MHRA has published its second-quarter results report and a letter from Lawrence Tallon. Monthly reporting of performance indicators and regulatory timelines will continue.

Ersin ÇETİNMDR Auditor
Türkçe oku
Conceptual regulatory reporting illustration with quarterly reports, calendar blocks and medical-device silhouettes
AI-generated conceptual illustration, not a photograph of an actual event.

What Changed

The Medicines and Healthcare products Regulatory Agency (MHRA) has added its second-quarter results report to its quarterly Results and Forecast publication for 2026–2027. The addition, dated 12 November 2026, includes an accompanying letter from Lawrence Tallon.

The second-quarter report is a 13-page PDF, while the letter is one page. The publication page also retains the 12-page first-quarter report and a two-page letter from Julian Beach.

Who Is Affected

The reporting is aimed at customers monitoring MHRA service performance and priorities. For medical-device manufacturers and regulatory teams, its relevance is the agency’s reporting on regulatory timelines and organisational performance.

MHRA describes predictable, reliable service delivery as a priority and presents quarterly reporting as part of its commitment to transparency about performance, impact and future priorities.

Regulatory and Technical Implications

The quarterly reports cover regulatory timelines, organisational performance measures and priorities for the following quarter. This is a corporate performance publication rather than a new technical regulation.

MHRA says key performance indicator data and expected completion timelines for specific regulatory functions will continue to be reported monthly through its established MHRA Performance Data page.

Manufacturer Actions

Manufacturers can consult the second-quarter report and accompanying letter to follow the agency’s quarterly priorities. Teams checking expected timelines for particular regulatory functions should distinguish this quarterly reporting from the separate monthly performance data.

The publication page does not announce a new manufacturer compliance obligation or submission deadline.

Confirmed Dates

The publication page was first published on 13 August 2026. The second-quarter results and Lawrence Tallon’s letter were added on 12 November 2026. These are publication-history dates.

Official Source

MHRA’s official GOV.UK publication: MHRA quarterly Results and Forecast: 2026 to 2027.

Https://www.gov.uk/government/publications/mhra-quarterly-results-and-forecast-2026-to-2027

Source and related services

Corporate report: MHRA quarterly Results and Forecast: 2026 to 2027 ↗

Source date: 12/11/2026

This news provides general information and does not replace device-specific legal or conformity assessment advice.

Related news

MHRA 2030 Strategy sets direction for AI devices and lifecycle data →MHRA publishes 2030 strategy explainers for MedTech and other stakeholders →MHRA announces recall of one Accord-UK lercanidipine 10 mg batch →
Contact an MDR Expert